Adam Crystal - 01 Mar 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
President, Research & Development
Signature
/s/ Douglas Barry, attorney-in-fact
Issuer symbol
TNGX
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 15:10:29 UTC
Previous filing
02 Mar 2023
Next filing
02 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Award $0 +81,250 $0.000000 81,250 01 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +487,500 $0.000000 487,500 01 Mar 2023 Common Stock 487,500 $5.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Remarks:

President, Research & Development